FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer

CORCEPT THERAPEUTICS INC

Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).
Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).
Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.